A new study could lead to a non-invasive test that would let expecting mothers know the sex of their baby as early as the first trimester.
Researchers from South Korea discovered that various ratios of two enzymes (DYS14/GAPDH) extracted from a pregnant mother’s blood indicate if the baby will be a boy or a girl. Such a test would be the first of its kind.
“Generally, early foetal gender determination has been performed by invasive procedures such as chorionic villus sampling or amniocentesis. However, these invasive procedures still carry a one to two per cent risk of miscarriage and cannot be performed until 11 weeks of gestation. Moreover, reliable determination of foetal gender using ultrasonography cannot be performed in the first trimester, because the development of external genitalia is not complete,” said study author Dr Hyun Mee Ryu, from the Department of Obstetrics and Gynaecology at Cheil General Hospital at the KwanDong University School of Medicine in Seoul, Korea.
“Therefore, this can reduce the need for invasive procedures in pregnant women carrying an X-linked chromosomal abnormality and clarify inconclusive readings by ultrasound.”
Dr Ryu and colleagues collected maternal plasma from 203 women during their first trimester of pregnancy. The presence of circulating foetal DNA was confirmed by a quantitative methylation-specific polymerase chain reaction of U-PDE9A.
Multiplex real-time polymerase chain reaction was used to simultaneously quantify the amount of DYS14 and GAPDH in maternal plasma. The results were confirmed by phenotype at birth.
“Although more work must be done before such a test is widely available, this paper does show it is possible to predict the sex of a child as early as the first few weeks after conception,” said Dr Ryu.
“At present, parents are sometimes given the wrong information about the sex of their unborn child; this test should prove helpful in resolving any uncertainties of today’s ultrasound observations.”
Image courtesy of Andrew Michaels, Creative Commons
